Sentences with phrase «synuclein for»

Not exact matches

For example, in sporadic PD, multiple GWAS point to the alpha - synuclein gene (SNCA) as one of the strongest risk loci in patients» genomes, yet GWAS contain little information regarding the mechanism of how this gene is dysregulated in sporadic PD patients.

These human genes were also protective against alpha - synuclein - induced death, suggesting that they could be worth testing as gene therapy treatments for Parkinson's disease, Lu says.

The study, published in the October edition of the journal Neurotherapeutics, found that the drug, AT2101, which has also been studied for Gaucher disease, improved motor function, stopped inflammation in the brain and reduced levels of alpha - synuclein, a protein critically involved in Parkinson's.

In the quest for an animal model of PD that mimics motor and non-motor symptoms of human PD, scientists have developed strains of mice that overexpress α - synuclein.

Melki, a protein researcher at the Paris - Saclay Institute of Neuroscience, is known for his ability to generate distinct types of alpha - synuclein.

If it emerges that it is indeed a «catcher's mitt» for α - synuclein, it could provide a drug target for a disease whose 10 million sufferers are sorely in need of new medicines.

«Activation of these cell receptors appear to prevent brain cells from cleaning out the trash — the toxic buildup of proteins, such as alpha - synuclein, tau and amyloid, common in neurodegenerative diseases,» says the study's senior author, neurologist Charbel Moussa, MBBS, PhD, director of Georgetown's Laboratory for Dementia and Parkinsonism, and scientific and clinical research director of the GUMC Translational Neurotherapeutics Program.

Last week, findings presented at the huge annual meeting of the Society for Neuroscience further buttressed the theory that spread of the rogue protein, called α - synuclein, is responsible for the progressive disease, which is marked by tremor, stiff movements, depression, and, ultimately, dementia.

This may allow damaged or degenerating neurons to maintain their function for longer than those who are less efficient at retaining α - synuclein.

Data from 304 PD patients followed for up to 8 years indicate that patients with higher cerebrospinal fluid (CSF) α - synuclein levels experienced faster cognitive decline in the following months, although no associations were found between α - synuclein levels and motor changes.

«One possible explanation is that UPDRS reflects primarily deficits arising from nigrostriatal degeneration, whereas CSF α - synuclein levels are influenced by the whole brain and may serve as a proxy for total brain pathology,» says Dr. Zhang.

For its journey from the brain to the stomach, alpha - synuclein only used the less abundant efferent vagal projections.

Holmes also found that HSPGs are essential for the cell - to - cell spread of corrupted forms of alpha - synuclein, a protein linked to Parkinson's disease.

Some of the genes have already been identified, such as parkin (ScienceNOW, 8 April 1998), which is responsible for Parkinson's type PARK2, and alpha - synuclein (ScienceNOW, 26 June 1997), which instigates type PARK1.

«The drugs that are going to be ideal for targeting [α - synuclein] have yet to be developed.»

- synuclein has been visualised in the cell for the first time.»

One of the trademarks of Parkinson's Disease, for example, is an excess of alpha - synuclein in the brain.

For example, it is known that α - synuclein has a very concrete structure, which means that it is based on a blueprint that follows a specific pattern.

For example, α - synuclein, a protein that has been linked to Parkinson disease and other neurodegenerative disorders, helps assemble the fusion apparatus and protects animals from age - related neurological problems.

Interplay between Sumoylation and Phosphorylation for Protection against α - Synuclein Inclusions.

For α - synuclein, Nrf2 accelerated the breakdown and clearance of the protein, reducing its levels in the cell.

302 No 5651 pp 1772 - 1775 «Yeast Cells Provide Insights into Alpha - Synuclein Biology and Pathology» Authors: Tiago Fleming Outeiro and Susan Lindquist Whitehead Institute for Biomedical Research, Cambridge, MA

In research published in this week's issue of the journal Science, a team from Whitehead Institute for Biomedical Research used common baker's yeast as a living test tube to show how just a small amount of a Parkinson's - related neuronal protein called alpha - synuclein (aSyn) can convince neighboring proteins to abandon their normal shape and form these deadly clusters.

α - synuclein in Saccharomyces cerevisiae: model for aggregate clearance, cell survival and influence of autophagy.

In the search for compounds that might alter a protein's behavior or function — such as that of alpha - synuclein — drug companies often rely on so - called target - based screens that test the effect large numbers of compounds have on the protein in question in rapid, automated fashion.

There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.

The clinical consortium is led by AFFiRiS itself, and in addition to the PD booster trial, it is now recruiting for a separate Phase I trial of the α - synuclein vaccine against MSA, a synucleinopathy differentiated from PD or LBD based on the cell populations affected, the regional concentration of AS neuropathology, and the spectrum of movement and other symptoms.

In further studies, for which Proclara received support from the Michael J. Fox Foundation, NPT088 reduced levels of alpha - synuclein aggregates in an animal model of Parkinson's disease.

The clustering of this protein, alpha - synuclein, is the hallmark of Parkinson's and dementia with Lewy bodies, suggesting a new potential compound for therapeutic research.

The clustering of this protein, alpha - synuclein (α - synuclein), is the hallmark of Parkinson's disease and dementia with Lewy bodies, suggesting a new potential compound for therapeutic research.

MAIN OUTCOME MEASURES: Neuropathological and biochemical examination of the brain using standardized evaluation for tau, beta - amyloid, and synuclein deposits.

The animal model used for this study, C. elegans, is a nematode worm genetically engineered to produce human α - synuclein in its muscles.

The neuropathological semiquantitative score for alpha - synuclein aggregation was 4.

The clustering of this protein, alpha - synuclein (α - synuclein), is the hallmark of Parkinson's and dementia with Lewy bodies, suggesting a new potential compound for therapeutic research.

In this study, the researchers demonstrated in a series of in vitro experiments that squalamine, a positively charged molecule with a high affinity for negatively charged membranes, could literally «kick off» α - synuclein from negatively charged membranes, where the protein binds, preventing the formation of the toxic clumps.

«Our findings raise the possibility that an immunotherapy approach could be used to increase the immune system's tolerance for alpha - synuclein, which could help to ameliorate or prevent worsening symptoms in Parkinson's disease patients,» said Dr. Sette.

Columbia University filed a patent application for use of alpha - synuclein peptides as biomarkers (US Patent Application No. 15/300, 713).

Twenty - two sections of paraffin - embedded tissue were stained for Luxol fast blue, hematoxylin and eosin, Bielschowsky silver, phosphorylated tau (ptau)(AT8), α - synuclein, amyloid - β, and phosphorylated transactive response DNA binding protein 43 kDa (pTDP - 43) using methods described previously.16 In some cases, large coronal slabs of the cerebral hemispheres were also cut at 50 μm on a sledge microtome and stained as free - floating sections using AT8 or CP - 13.16,17